Hillsdale Investment Management’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $101K | Sell |
1,670
-21,000
| -93% | -$1.22M | ﹤0.01% | 577 |
|
|
2025
Q4 | $1.22M | Buy |
22,670
+2,000
| +10% | +$96.2K | 0.03% | 339 |
|
|
2025
Q3 | $932K | Buy |
20,670
+6,330
| +44% | +$296K | 0.03% | 367 |
|
|
2025
Q2 | $664K | Sell |
14,340
-300
| -2% | -$14.7K | 0.02% | 374 |
|
|
2025
Q1 | $893K | Buy |
14,640
+640
| +5% | +$37.3K | 0.05% | 262 |
|
|
2024
Q4 | $792K | Buy |
14,000
+13,600
| +3,400% | +$760K | 0.04% | 278 |
|
|
2024
Q3 | $20.7K | Buy |
+400
| New | +$18.8K | ﹤0.01% | 471 |
|
|
2024
Q2 | – | Sell |
-1,394
| Closed | -$75.6K | – | 584 |
|
|
2024
Q1 | $75.6K | Sell |
1,394
-830
| -37% | -$42.3K | 0.01% | 439 |
|
|
2023
Q4 | $114K | Hold |
2,224
| – | – | 0.01% | 402 |
|
|
2023
Q3 | $129K | Sell |
2,224
-6,630
| -75% | -$406K | 0.01% | 378 |
|
|
2023
Q2 | $566K | Hold |
8,854
| – | – | 0.05% | 221 |
|
|
2023
Q1 | $614K | Sell |
8,854
-100
| -1% | -$7.05K | 0.05% | 270 |
|
|
2022
Q4 | $644K | Sell |
8,954
-1,020
| -10% | -$76.9K | 0.05% | 268 |
|
|
2022
Q3 | $709K | Buy |
9,974
+196
| +2% | +$14.2K | 0.06% | 238 |
|
|
2022
Q2 | $753K | Sell |
9,778
-400
| -4% | -$30.5K | 0.06% | 233 |
|
|
2022
Q1 | $744K | Buy |
10,178
+200
| +2% | +$13.4K | 0.05% | 293 |
|
|
2021
Q4 | $621K | Hold |
9,978
| – | – | 0.04% | 350 |
|
|
2021
Q3 | $590K | Buy |
9,978
+9,000
| +920% | +$593K | 0.05% | 363 |
|
|
2021
Q2 | $65K | Sell |
978
-812
| -45% | -$52.9K | 0.01% | 447 |
|
|
2021
Q1 | $113K | Buy |
1,790
+130
| +8% | +$8.09K | 0.01% | 422 |
|
|
2020
Q4 | $103K | Sell |
1,660
-7,490
| -82% | -$461K | 0.01% | 408 |
|
|
2020
Q3 | $552K | Sell |
9,150
-320
| -3% | -$19.3K | 0.05% | 296 |
|
|
2020
Q2 | $557K | Sell |
9,470
-100
| -1% | -$5.98K | 0.05% | 300 |
|
|
2020
Q1 | $533K | Buy |
9,570
+8,170
| +584% | +$499K | 0.06% | 279 |
|
|
2019
Q4 | $90K | Hold |
1,400
| – | – | 0.01% | 421 |
|
|
2019
Q3 | $71K | Sell |
1,400
-660
| -32% | -$31K | 0.01% | 430 |
|
|
2019
Q2 | $93K | Sell |
2,060
-8,850
| -81% | -$412K | 0.01% | 426 |
|
|
2019
Q1 | $521K | Buy |
10,910
+3,410
| +45% | +$170K | 0.05% | 299 |
|
|
2018
Q4 | $390K | Hold |
7,500
| – | – | 0.05% | 328 |
|
|
2018
Q3 | $466K | Hold |
7,500
| – | – | 0.06% | 192 |
|
|
2018
Q2 | $415K | Buy |
+7,500
| New | +$405K | 0.05% | 226 |
|
|
2018
Q1 | – | Sell |
-5,840
| Closed | -$358K | – | 472 |
|
|
2017
Q4 | $358K | Hold |
5,840
| – | – | 0.06% | 269 |
|
|
2017
Q3 | $372K | Hold |
5,840
| – | – | 0.06% | 238 |
|
|
2017
Q2 | $326K | Buy |
+5,840
| New | +$318K | 0.06% | 231 |
|
|
2013
Q4 | – | Sell |
-1,400
| Closed | -$65K | – | 540 |
|
|
2013
Q3 | $65K | Sell |
1,400
-200
| -13% | -$8.78K | 0.02% | 386 |
|
|
2013
Q2 | $72K | Buy |
+1,600
| New | +$69.5K | 0.02% | 392 |
|
Other funds holding BMY
VCM
VPM
Hillsdale Investment Management's BMY Position: Q1 2026 in Review
Hillsdale Investment Management reduced its Bristol-Myers Squibb (BMY) stake by 93% in Q1 2026, selling an estimated $1.22M and leaving 1,670 shares worth $101K. The position accounts for ﹤0.01% of the portfolio, ranked #577.
Hillsdale Investment Management first reported a position in BMY in Q2 2013 and has held it in 36 quarters since. The position peaked at $1.22M in Q4 2025. 2,521 funds tracked by Wall St. Rank hold BMY as of Q1 2026.
- Hillsdale Investment Management held 1,670 shares of Bristol-Myers Squibb worth $101K as of Q1 2026.
- Hillsdale Investment Management sold 21,000 Bristol-Myers Squibb shares in Q1 2026, an estimated $1.22M.
- Bristol-Myers Squibb made up ﹤0.01% of Hillsdale Investment Management's portfolio in Q1 2026, its #577 holding.
- Hillsdale Investment Management first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 36 quarters since.
- Hillsdale Investment Management's Bristol-Myers Squibb position peaked at $1.22M in Q4 2025.
- 2,521 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.
Based on Hillsdale Investment Management's 13F filing for Q1 2026, filed 4 May 2026.